ClinicalTrials.gg
RecruitingNCT07359599IRON-PHUpdated Jan 30, 2026

The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension

A Phase 4 interventional study of Ferric Carboxymaltose (FCM) and Sodium Chloride (NaCl) 0.9 % in Pulmonary Hypertension and Iron Deficiency, sponsored by Ziekenhuis Oost-Limburg. Recruiting at 7 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Ziekenhuis Oost-Limburg · Phase 4, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Hypertension, Pulmonary with a site in Belgium — 11 open to participants now, 17 under way, 5 of them phase 3. Hypertension, Pulmonary · Belgium.

Planned enrollment
16th of 57
306 · median 185
Started
2026
with 3 others
Phase 4
2 of 70
1 open now
Primary completion
2028-07
later than 13 of 16 live
Registered
70th of 70
by date

Among the 70 studies in Hypertension, Pulmonary with a site in Belgium, this one is the 16th largest by planned enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 in phase 4, reaches primary completion later than 13 of the 16 other live ones, and was the 70th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

11 of the 70 studies in Hypertension, Pulmonary with a site in Belgium are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Hypertension, Pulmonary with a site in Belgium, or all of them as a file.
02

Study summary

Pulmonary hypertension (PH) is a condition characterized by elevated blood pressure in the pulmonary arteries. This leads to symptoms such as shortness of breath and a significantly reduced exercise capacity, resulting in a very poor quality of life. Currently, treatment options for PH are limited.

More than 60% of patients with PH develop iron deficiency. Studies have shown that this deficiency is associated with more severe symptoms, reduced exercise capacity, and even lower quality of life. Oral iron supplements are often ineffective in these patients due to impaired absorption in the intestines, caused by chronic low-grade inflammation-a common feature in PH.

Intravenous iron administration can rapidly correct the deficiency, but it remains unclear whether this also leads to clinical improvements such as enhanced exercise capacity, reduced shortness of breath, and improved quality of life. Moreover, the cost-effectiveness of this treatment is still unknown. The IRON-PH study aims to answer these questions.

As part of the IRON-PH study, 306 patients with pulmonary hypertension will be enrolled. Each patient will be randomized to receive either intravenous iron (ferric carboxymaltose) or intravenous placebo (NaCl 0.9%).

03

Conditions studied

  • Pulmonary Hypertension
  • Iron Deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • WHO functional class II - IV
  • Iron deficiency defined as TSAT \<21% (no more than ≥3 months old at randomization)
  • PH defined by echocardiography and/or right heart catheterization (RHC) according to the following WHO groups:

    • Group 1 PH:

      • Patients with a diagnosis of idiopathic PAH, hereditary PAH, drug induced PAH or PAH and associated with CTD or CHD (historical RHC available) on stable and optimized doses of PAH targeted therapies for at least 4 weeks before randomization.
      • Echocardiographic evidence of a high or intermediate probability for PH as per 2022 ESC PH guidelines.
    • Group 2 PH and baseline > 50% on imaging modality within last 6 months before randomization and on stable doses of loop diuretics and HFpEF therapies for 4 weeks. Group 2 PH can be included based on echocardiography or RHC.:

      • Echocardiography (\<6mo before randomization):

        • Presence of LVH or LA-enlargement
        • E/e' >15 (at rest or exercise)
        • TRVmax >2.8 m/s (at rest) or mPAP/CO>3 mHg/L/min (exercise) or echocardiographic evidence of high or intermediate probability for PH as per 2022 ESC PH guidelines.
      • RHC (\<6mo before randomization)

        • mPAP > 20 mmHg
        • PCWP > 15 mmHg at rest or PCWP/CO-slope > 2mmHg/L/min or exercise PCWP>25mmHg, or PCWP 13-15 mmHg with elevation ≥18mmHg after 500 cc Fluid Challenge
    • Group 4 PH:

      • Inoperable CTEPH
      • Persistent/recurrent CTEPH (> 1 year after endarterectomy or > 6 months after balloon pulmonary angioplasty) ineligible for balloon pulmonary angioplasty.
      • Echocardiographic evidence of a high or intermediate probability for PH as per 2022 ESC PH guidelines.

Exclusion criteria

Exclusion Criteria:

  • Screening \< 8 g/dl or >15 g/dl
  • Ferritin > 700 ng/mL
  • Known reaction to any component of FCM
  • Group 1 PH associated with veno-occlusive diseases.
  • Primary diagnosis of group 3 PH
  • Primary diagnosis of group 5 PH
  • Treatment with oral or other IV iron therapies at screening.
  • Current or planned mechanical circulatory support or lung/heart transplantation.
  • Any planned surgery or procedure leading to expected significant blood loss (defined as more than 250 ml = equal to 125mg of iron).
  • Haemodialysis or peritoneal dialysis (current or planned within the next 24 weeks).
  • Inability to return for follow up visits within the necessary windows
  • Concurrently in a study with another product.
  • Uncorrected moderate to severe aortic stenosis (AVA \<1.5cm² and mean gradient >20 mmHg) or severe valvular regurgitation (except tricuspid regurgitation)
  • Impression by investigator that patient cannot perform a 6MWT
  • Active infection as judged by the investigator.
  • Pregnancy or desire to become pregnant during the study duration.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
306 participants (estimated)

Study arms

  • Experimental
    Ferric carboxymaltose

    Drug: Ferric Carboxymaltose (FCM)

  • Placebo comparator
    Placebo

    Drug: Sodium Chloride (NaCl) 0.9 %

Interventions

  • DrugFerric carboxymaltoseStudies of Ferric carboxymaltoseFerric carboxymaltose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ferric Carboxymaltose (FCM), dosing and administration according to SmPC guidelines

  • DrugSodium Chloride (NaCl) 0.9 %

    Placebo, dosing and administration according to SmPC guidelines

06

What researchers measure

Primary outcomes

  1. Change in 6MWD

    Change in 6-minute walking distance (6MWD) from baseline to 24 week follow-up

    Time frame: From baseline to 24 week follow-up

Secondary outcomes

  1. Change in MLHFQ

    Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) score from baseline to 24 week follow-up. Total Score: Sum of all 21 items (0-105) Higher Score = Worse QoL: A higher number indicates a greater negative impact from heart failure Lower Score = Better QoL: A lower score suggests less limitation

    Time frame: Baseline to 24 week follow-up

  2. Change in EQ5D5L

    Change in EuroQol 5 dimensions - 5 levels questionnaire score from baseline to 24 week follow-up EQ-5D-5L combiines responses from five health dimensions, each with five severity levels to create a 5-digit health state code, then applying country-specific "value sets" (valuation matrices) to convert this code into a single Index Score (Utility Score), ranging from \<0 (worst) to 1 (best health), plus a separate EQ-VAS score (0-100) for overall self-rated health. Dimensions: Mobility, self-care, usual activities, pain/discomfort, anxiey/depression Levels: 1 no problem, 2 slight problems, 3 moderate problems, 4 severe problems, 5 unable to/extreme problems Example of 5-digit state code: 12345 indicates no problems with mobility, slight problems with self-care, moderate problems with usual activities, severe pain/discomfort and extreme anxiety/depression

    Time frame: Baseline to 24 week follow-up

  3. Change in FSS

    Change in Fatigue Severity Scale (FSS) score from baseline to 24 weeks Total score: sum of all scores (ranging between 9 - 63) Higher Scores = More Fatigue Lower Scores = Less Fatigue

    Time frame: Baseline to 24 week follow-up

  4. Developing composite clinical worsening event

    The hazard ratio between treatment arms in developing the composite clinical worsening event in the overall trial population

    Time frame: From first patient Day 1 (Baseline) to study completion, an average of 2 years

07

Study locations

1 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2028, 30 months after the start.

Of 23 phase 4 interventional studies under Hypertension, Pulmonary, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 54. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 22, 2026
StartActual
Jan 27, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Oct 2028
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359599
Lead sponsor
Ziekenhuis Oost-Limburg
Collaborators
Federal Knowledge Centre (KCE)
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Jan 27, 2026
Primary completion
Jul 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Jan 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion